Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG: 0874)

Market Cap	45.11B
Revenue (ttm)	84.61B
Net Income (ttm)	3.79B
Shares Out	1.63B
EPS (ttm)	2.33
PE Ratio	7.63
Forward PE	7.46
Dividend	0.85 (4.68%)
Ex-Dividend Date	Oct 15, 2024

Volume	870,000
Open	18.28
Previous Close	18.20
Day's Range	18.14 - 18.36
52-Week Range	16.62 - 24.20
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About Guangzhou Baiyunshan Pharmaceutical Holdings Company

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, medical ins...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1997
• Employees: 28,048
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0874

Financial Performance

In 2023, Guangzhou Baiyunshan Pharmaceutical Holdings Company's revenue was 75.52 billion, an increase of 6.68% compared to the previous year's 70.79 billion. Earnings were 4.06 billion, an increase of 2.25%.

Financial numbers in CNY